1) Photochemical lysis (PCL)  
In 2022, PCI Biotech initiated a programme to develop a new photochemical technology, PCL, for increasing yield and reducing impurities in viral vector manufacturing. There is a great need for novel technologies that enable more effective manufacturing, and PCI Biotech’s objective is to replace existing cell lysis methods. As such, the technology shall be applied to extract viral vectors from producer cells while reducing host-cell impurities, by selective disruption of producer cell membranes during the cell lysis process.

2) Photochemical internalisation (PCI)          
Several novel classes of drugs (e.g. gene therapies and certain immunotherapeutics) need access to the inside of their human target cells, such as tumour cells or immune cells, in order to be effective. Pharmaceutical companies struggle to find effective drug delivery methods, in order to achieve the full therapeutic and commercial potential of their products. The PCI technology may unlock this potential by modifying the intracellular trafficking in target cells, leading to enhanced biological effect of medicinal products. Development of PCI is focussed on dermatological and intratumoural applications.

PCI Biotech is a member of Oslo Cancer Cluster, an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines. Oslo Cancer Cluster is a national non-profit member organisation for Norwegian and international companies, research and financial institutions, university hospitals and organisations – all working in the cancer field.
Read more about Oslo Cancer Cluster here: